Correlative serologic studies between alemtuzumab-treated patients with and without ITP
| . | ITP (n = 6) . | Non-ITP (n = 210) . | ||||
|---|---|---|---|---|---|---|
| No. evaluable at baseline . | Positive at baseline, n (%) . | Seroconversion, n (%)* . | No. evaluable at baseline . | Positive at baseline, n (%) . | Seroconversion, n (%)* . | |
| Serum antiplatelet Abs | 6 | 1 (16.7) | 2 (40.0) | 200 | 13 (6.5) | 18 (9.6) |
| Anti-TSH receptor Abs | 6 | 0 | 2 (33.3) | 210 | 0 | 79 (37.6) |
| Anti–thyroid peroxidase Abs | 6 | 0 | 2 (33.3) | 200 | 16 (8.0) | 48 (26.1) |
| . | ITP (n = 6) . | Non-ITP (n = 210) . | ||||
|---|---|---|---|---|---|---|
| No. evaluable at baseline . | Positive at baseline, n (%) . | Seroconversion, n (%)* . | No. evaluable at baseline . | Positive at baseline, n (%) . | Seroconversion, n (%)* . | |
| Serum antiplatelet Abs | 6 | 1 (16.7) | 2 (40.0) | 200 | 13 (6.5) | 18 (9.6) |
| Anti-TSH receptor Abs | 6 | 0 | 2 (33.3) | 210 | 0 | 79 (37.6) |
| Anti–thyroid peroxidase Abs | 6 | 0 | 2 (33.3) | 200 | 16 (8.0) | 48 (26.1) |
Defined as negative serology at baseline and positive serology on ≥ 1 occasions after alemtuzumab exposure.